Effects of SNPs on Gene Regulation in Complex Diseases

Information

  • Research Project
  • 6694876
  • ApplicationId
    6694876
  • Core Project Number
    R44GM069291
  • Full Project Number
    1R44GM069291-01
  • Serial Number
    69291
  • FOA Number
    PA-02-10
  • Sub Project Id
  • Project Start Date
    8/1/2003 - 20 years ago
  • Project End Date
    1/31/2004 - 20 years ago
  • Program Officer Name
    BROOKS, LISA
  • Budget Start Date
    8/1/2003 - 20 years ago
  • Budget End Date
    1/31/2004 - 20 years ago
  • Fiscal Year
    2003
  • Support Year
    1
  • Suffix
  • Award Notice Date
    7/21/2003 - 20 years ago

Effects of SNPs on Gene Regulation in Complex Diseases

DESCRIPTION (provided by applicant): ADAM33 has been identified as an Asthma susceptibility gene. A set of disease-associated single nucleotide polymorphisms (SNPs) have been identified that confer no obvious perturbation on the expressed transcript or the protein that it encodes. We hypothesize that in asthma and other complex diseases, associated SNPs act to perturb the efficiency of DNA/RNA sequence elements, which recruit the proteins that regulate transcription and modulate splicing. Such perturbations in several genes could exert subtle effects on the phenotypic display. Our strategy in Phase I will be to utilize computational approaches to perform a comprehensive search within the ADAM33 gene to predict the location of the transcription regulatory and splicing elements (TRASEs). We will develop a visualization tool to display the TRASEs and the SNPs onto the gene structure of ADAM33. New SNPs will be identified. Statistical analysis will be employed to prioritize the most significant SNP pair haplotypes. We will use the haplotypes to address our hypothesis in Phase II. Our goals in this fast track proposal are to achieve a better understanding of the genetic factors that affect susceptibility to complex diseases and their expression. We will use this knowledge to identify new drug targets that can lead to the development of new therapeutic agents.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R44
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    210882
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    821
  • Ed Inst. Type
  • Funding ICs
    NIGMS:210882\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    OSCIENT PHARMACEUTICALS CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    WALTHAM
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    024538443
  • Organization District
    UNITED STATES